• Explore /
  • Poster
  • / A phase 2 study of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following abiraterone and/or enzalutamide (abi/enz).

A phase 2 study of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following abiraterone and/or enzalutamide (abi/enz).

Abstract Poster

Authors

Daniel Petrylak

Daniel Peter Petrylak

Yale University Medical Center, New Haven, CT

Daniel Peter Petrylak , Nicholas J. Vogelzang , Gurkamal S. Chatta , Mark T. Fleming , David C. Smith , Leonard Joseph Appleman , Arif Hussain , Manuel Modiano , Parminder Singh , Scott T. Tagawa , Ira Gore , Edward Francis McClay , Anthony E. Mega , A. Oliver Sartor , Bradley G. Somer , Raymond Couric Wadlow , Neal D. Shore , Nancy Stambler , Vincent A. DiPippo , Robert Joseph Israel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session A: Prostate Cancer

Track

Prostate Cancer

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT01695044

Citation

J Clin Oncol 33, 2015 (suppl 7; abstr 144)

DOI

10.1200/jco.2015.33.7_suppl.144

Abstract #

144

Poster Bd #

G6

Abstract Disclosures

Similar Posters

First Author: Daniel Peter Petrylak

First Author: Daniel Peter Petrylak

First Author: Louise Emmett

First Author: Daniel P. Petrylak